Blood Protein Signature Reported for Diabetic Kidney Disease
By LabMedica International staff writers Posted on 09 May 2019 |
Image: Nodular glomerulosclerosis in the kidney of a patient with diabetic nephropathy; the acellular light purple areas within the capillary tufts are the destructive mesangial matrix deposits (Photo courtesy of the CDC).
Diabetic nephropathy or diabetic kidney disease (DKD), is a result of vascular abnormalities that accompany diabetes and increases mortality risk. Furthermore, diabetes mellitus is a main risk factor for end-stage renal disease, the most advanced stage of kidney disease.
Chronic inflammation is postulated to be involved in the development of end-stage renal disease in diabetes, but which specific circulating inflammatory proteins contribute to this risk remain unknown. End-stage renal disease (ESRD) in diabetes is a life threatening complication resulting in a poor prognosis for patients as well as high medical costs.
An international team of scientists led by the Harvard Medical School (Boston, MA, USA) examined 194 circulating inflammatory proteins in subjects from three independent cohorts with type 1 and type 2 diabetes. In each cohort, they identified an extremely robust kidney risk inflammatory signature (KRIS), consisting of 17 proteins enriched in tumor necrosis factor-receptor superfamily members, that was associated with a 10-year risk of end-stage renal disease. All these proteins had a systemic, non-kidney source.
The type 1 diabetes group included 108 individuals who developed end-stage renal disease during the study's follow up time, while 35 of the individuals with type 2 diabetes had kidney disease that advanced to that point. Half a dozen of the proteins came from tumor necrosis factor receptor super-families, while the remaining proteins represented receptor or secreted proteins. The team used a custom SOMAscan array (SomaLogic, Boulder, CO, USA), and assessed 194 circulating proteins, focusing on inflammatory proteins and proteins previously implicated in diabetic kidney disease, in blood samples from 219 individuals with type 1 diabetes and a validation group of 144 type 2 diabetes patients, all with some level of kidney impairment.
The authors concluded that these proteins point to new therapeutic targets and new prognostic tests to identify subjects at risk of end-stage renal disease, as well as biomarkers to measure responses to treatment of diabetic kidney disease. Andrzej S. Krolewski, MD, PhD, the senior author of the study, said, “These proteins point to new therapeutic targets and new prognostic tests to identify subjects at risk of end-stage renal disease, as well as biomarkers to measure responses to treatment of diabetic kidney disease.” The study was published on April 22, 2019, in the journal Nature Medicine.
Related Links:
Harvard Medical School
SomaLogic
Chronic inflammation is postulated to be involved in the development of end-stage renal disease in diabetes, but which specific circulating inflammatory proteins contribute to this risk remain unknown. End-stage renal disease (ESRD) in diabetes is a life threatening complication resulting in a poor prognosis for patients as well as high medical costs.
An international team of scientists led by the Harvard Medical School (Boston, MA, USA) examined 194 circulating inflammatory proteins in subjects from three independent cohorts with type 1 and type 2 diabetes. In each cohort, they identified an extremely robust kidney risk inflammatory signature (KRIS), consisting of 17 proteins enriched in tumor necrosis factor-receptor superfamily members, that was associated with a 10-year risk of end-stage renal disease. All these proteins had a systemic, non-kidney source.
The type 1 diabetes group included 108 individuals who developed end-stage renal disease during the study's follow up time, while 35 of the individuals with type 2 diabetes had kidney disease that advanced to that point. Half a dozen of the proteins came from tumor necrosis factor receptor super-families, while the remaining proteins represented receptor or secreted proteins. The team used a custom SOMAscan array (SomaLogic, Boulder, CO, USA), and assessed 194 circulating proteins, focusing on inflammatory proteins and proteins previously implicated in diabetic kidney disease, in blood samples from 219 individuals with type 1 diabetes and a validation group of 144 type 2 diabetes patients, all with some level of kidney impairment.
The authors concluded that these proteins point to new therapeutic targets and new prognostic tests to identify subjects at risk of end-stage renal disease, as well as biomarkers to measure responses to treatment of diabetic kidney disease. Andrzej S. Krolewski, MD, PhD, the senior author of the study, said, “These proteins point to new therapeutic targets and new prognostic tests to identify subjects at risk of end-stage renal disease, as well as biomarkers to measure responses to treatment of diabetic kidney disease.” The study was published on April 22, 2019, in the journal Nature Medicine.
Related Links:
Harvard Medical School
SomaLogic
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes